- Home
- ATHA vs LPTX Comparison
ATHA vs LPTX Comparison
Compare ATHA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- LPTX
- Stock Information
- Founded
- ATHA 2011
- LPTX 2011
- Country
- ATHA United States
- LPTX United States
- Employees
- ATHA N/A
- LPTX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATHA Health Care
- LPTX Health Care
- Exchange
- ATHA Nasdaq
- LPTX Nasdaq
- Market Cap
- ATHA 15.7M
- LPTX 14.7M
- IPO Year
- ATHA 2020
- LPTX N/A
- Fundamental
- Price
- ATHA $0.37
- LPTX $0.31
- Analyst Decision
- ATHA Buy
- LPTX Hold
- Analyst Count
- ATHA 4
- LPTX 1
- Target Price
- ATHA $11.25
- LPTX N/A
- AVG Volume (30 Days)
- ATHA 293.7K
- LPTX 342.1K
- Earning Date
- ATHA 08-12-2025
- LPTX 08-11-2025
- Dividend Yield
- ATHA N/A
- LPTX N/A
- EPS Growth
- ATHA N/A
- LPTX N/A
- EPS
- ATHA N/A
- LPTX N/A
- Revenue
- ATHA N/A
- LPTX N/A
- Revenue This Year
- ATHA N/A
- LPTX N/A
- Revenue Next Year
- ATHA N/A
- LPTX N/A
- P/E Ratio
- ATHA N/A
- LPTX N/A
- Revenue Growth
- ATHA N/A
- LPTX N/A
- 52 Week Low
- ATHA $0.22
- LPTX $0.22
- 52 Week High
- ATHA $3.67
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ATHA 47.14
- LPTX 39.73
- Support Level
- ATHA $0.34
- LPTX $0.33
- Resistance Level
- ATHA $0.51
- LPTX $0.38
- Average True Range (ATR)
- ATHA 0.05
- LPTX 0.03
- MACD
- ATHA -0.01
- LPTX -0.00
- Stochastic Oscillator
- ATHA 25.41
- LPTX 22.27
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.